As previously reported, CCNE1 amplification was detected in colorectal cancer patients and both increased and decreased expression of CCNE1 were found to be associated with drug resistance in colon cancer, depending on the therapeutics used [49, 50]. Here, CCNE1 is linked to malignant colon neoplasm.